File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations

TitleResistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations
Authors
KeywordsBacteroides stercoris
BCAAs
gut microbiota
intrahepatic triglyceride content
lipopolysaccharides
microbiota transplantation
microbiota-directed foods
non-alcoholic fatty liver disease
resistant starch
Issue Date5-Sep-2023
PublisherCell Press
Citation
Cell Metabolism, 2023, v. 35, n. 9, p. 1530-1547 How to Cite?
AbstractNon-alcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic dysfunction for which effective interventions are lacking. To investigate the effects of resistant starch (RS) as a microbiota-directed dietary supplement for NAFLD treatment, we coupled a 4-month randomized placebo-controlled clinical trial in individuals with NAFLD (ChiCTR-IOR-15007519) with metagenomics and metabolomics analysis. Relative to the control (n = 97), the RS intervention (n = 99) resulted in a 9.08% absolute reduction of intrahepatic triglyceride content (IHTC), which was 5.89% after adjusting for weight loss. Serum branched-chain amino acids (BCAAs) and gut microbial species, in particular Bacteroides stercoris, significantly correlated with IHTC and liver enzymes and were reduced by RS. Multi-omics integrative analyses revealed the interplay among gut microbiota changes, BCAA availability, and hepatic steatosis, with causality supported by fecal microbiota transplantation and monocolonization in mice. Thus, RS dietary supplementation might be a strategy for managing NAFLD by altering gut microbiota composition and functionality.
Persistent Identifierhttp://hdl.handle.net/10722/338194
ISSN
2023 Impact Factor: 27.7
2023 SCImago Journal Rankings: 11.406
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorNi, Y-
dc.contributor.authorQian, L-
dc.contributor.authorSiliceo, SL-
dc.contributor.authorLong, X-
dc.contributor.authorNychas, E-
dc.contributor.authorLiu, Y-
dc.contributor.authorIsmaiah, MJ-
dc.contributor.authorLeung, H-
dc.contributor.authorZhang, L-
dc.contributor.authorGao, Q-
dc.contributor.authorWu, Q-
dc.contributor.authorZhang, Y-
dc.contributor.authorJia, X-
dc.contributor.authorLiu, S-
dc.contributor.authorYuan, R-
dc.contributor.authorZhou, L-
dc.contributor.authorWang, X-
dc.contributor.authorLi, Q-
dc.contributor.authorZhao, Y-
dc.contributor.authorEl-Nezami, H-
dc.contributor.authorXu, A-
dc.contributor.authorXu, G-
dc.contributor.authorLi, H-
dc.contributor.authorPanagiotou, G-
dc.contributor.authorJia, W-
dc.date.accessioned2024-03-11T10:26:58Z-
dc.date.available2024-03-11T10:26:58Z-
dc.date.issued2023-09-05-
dc.identifier.citationCell Metabolism, 2023, v. 35, n. 9, p. 1530-1547-
dc.identifier.issn1550-4131-
dc.identifier.urihttp://hdl.handle.net/10722/338194-
dc.description.abstractNon-alcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic dysfunction for which effective interventions are lacking. To investigate the effects of resistant starch (RS) as a microbiota-directed dietary supplement for NAFLD treatment, we coupled a 4-month randomized placebo-controlled clinical trial in individuals with NAFLD (ChiCTR-IOR-15007519) with metagenomics and metabolomics analysis. Relative to the control (n = 97), the RS intervention (n = 99) resulted in a 9.08% absolute reduction of intrahepatic triglyceride content (IHTC), which was 5.89% after adjusting for weight loss. Serum branched-chain amino acids (BCAAs) and gut microbial species, in particular Bacteroides stercoris, significantly correlated with IHTC and liver enzymes and were reduced by RS. Multi-omics integrative analyses revealed the interplay among gut microbiota changes, BCAA availability, and hepatic steatosis, with causality supported by fecal microbiota transplantation and monocolonization in mice. Thus, RS dietary supplementation might be a strategy for managing NAFLD by altering gut microbiota composition and functionality.-
dc.languageeng-
dc.publisherCell Press-
dc.relation.ispartofCell Metabolism-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectBacteroides stercoris-
dc.subjectBCAAs-
dc.subjectgut microbiota-
dc.subjectintrahepatic triglyceride content-
dc.subjectlipopolysaccharides-
dc.subjectmicrobiota transplantation-
dc.subjectmicrobiota-directed foods-
dc.subjectnon-alcoholic fatty liver disease-
dc.subjectresistant starch-
dc.titleResistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations-
dc.typeArticle-
dc.identifier.doi10.1016/j.cmet.2023.08.002-
dc.identifier.pmid37673036-
dc.identifier.scopuseid_2-s2.0-85169846651-
dc.identifier.volume35-
dc.identifier.issue9-
dc.identifier.spage1530-
dc.identifier.epage1547-
dc.identifier.eissn1932-7420-
dc.identifier.isiWOS:001073834800001-
dc.identifier.issnl1550-4131-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats